US Patent 8,784,878: Testosterone Transdermal Composition Claims, Expiration, Orange Book Status, and Generic Risk

US Patent 8,784,878 protects a narrow testosterone transdermal formulation platform associated with the Axiron-type delivery system. Its central limitation is not testosterone alone. The claims require testosterone, octyl salicylate or Padimate O, and ethanol or isopropanol in defined concentration ranges, with evaporation producing an amorphous deposit containing testosterone and the penetration enhancer.

The patent has a composition claim, a closed-formulation claim, a composition-use claim, and dependent claims directed to the testosterone-to-enhancer ratio and octyl salicylate. The ordinary patent term runs to March 31, 2027, based on the earliest claimed priority date, subject to any patent-term adjustment recorded by the USPTO.[1]

What does US Patent 8,784,878 protect?

US 8,784,878 protects non-occlusive liquid or gel-forming testosterone compositions that leave an amorphous testosterone-containing deposit on the skin after solvent evaporation.

The core claim requires all of the following:

Required element	Claim requirement
Active pharmaceutical ingredient	Testosterone
Testosterone concentration	0.1% to 10% by weight
Penetration enhancer	Octyl salicylate, Padimate O, or both
Enhancer concentration	0.1% to 10% by weight
Volatile solvent	Ethanol, isopropanol, or a mixture
Solvent concentration	85% to 99.8% by weight
Administration	Transdermal and non-occlusive
Post-application structure	Amorphous deposit formed after solvent evaporation
Amorphous phase	Contains testosterone and the penetration enhancer

The patent therefore does not cover every testosterone gel, solution, spray, or transdermal product. A competing product that omits the specified penetration enhancer, uses a different solvent system, forms a crystalline rather than amorphous deposit, or falls outside the concentration ranges may avoid literal infringement of claim 1.

How broad is claim 1 of US 8,784,878?

Claim 1 is a combination claim with several independent limitations. Its scope is narrower than a conventional claim directed only to a testosterone formulation.

Testosterone range

The testosterone concentration must be from 0.1% to 10% by weight. The range is expressed as an inclusive numerical range under ordinary patent-claim interpretation.

A composition containing 0.05% testosterone would fall outside the stated range. A composition containing 12% testosterone would also fall outside the range unless a separate doctrine-of-equivalents theory applied.

Penetration-enhancer limitation

The claim uses a closed Markush group consisting of:

Octyl salicylate, also known as octisalate or ethylhexyl salicylate; and
Padimate O.

The claim does not expressly include common alternative enhancers such as isopropyl myristate, oleic acid, propylene glycol, lauric acid, terpenes, or dimethyl sulfoxide.

A formulation containing octyl salicylate plus another enhancer can still fall within claim 1 because the claim recites "one or more" enhancers selected from the specified group. The presence of an additional, non-listed enhancer does not automatically remove the composition from the claim, although it may affect other claim limitations.

Volatile-solvent limitation

The solvent must be ethanol, isopropanol, or a mixture of those solvents. Water, acetone, methanol, propylene glycol, and other solvents are not within the literal solvent Markush group unless they are present as additional components in a composition that still contains the claimed ethanol or isopropanol solvent system.

The solvent must account for 85% to 99.8% by weight. This high solvent loading supports rapid evaporation after application.

Amorphous-deposit limitation

The most technically significant limitation is the required post-application state. The formulation must form, at physiological temperatures and after solvent evaporation, an amorphous deposit containing testosterone and the penetration enhancer.

This limitation separates the patent from a formulation claim based only on ingredients. In an infringement dispute, relevant evidence could include:

X-ray powder diffraction;
Differential scanning calorimetry;
Polarized-light microscopy;
Raman or infrared spectroscopy;
Solid-state stability testing;
Skin-deposition studies; and
Formulation evaporation and recrystallization data.

The amorphous-deposit requirement creates both a potential validity distinction and an infringement issue. A generic manufacturer may argue that its product produces a molecularly dispersed solution, a crystalline precipitate, or another solid-state structure rather than the claimed amorphous phase.

What do claims 2 through 7 add?

Claim	Scope	Commercial significance
1	Broadest composition claim	Covers the specified testosterone, enhancer, solvent, concentration, and amorphous-deposit combination
2	Testosterone-to-enhancer molar ratio of 1:20 to 20:1	Adds a quantitative formulation constraint
3	Composition consists of testosterone, enhancer, solvent, and optional gelling agent	Narrows the formulation to a limited ingredient set
4	Enhancer is octyl salicylate	Targets the principal Axiron-type enhancer
5	Closed-formulation version of claim 1	Excludes ingredients outside the recited formulation components, subject to claim construction
6	Method of transdermally delivering testosterone by applying claim 1	Covers use of the claimed composition
7	Method using the claim 3 composition	Narrows the method to the limited formulation set

Claim 2: molar ratio

Claim 2 requires a testosterone-to-enhancer molar ratio from 1:20 to 20:1. This is a broad ratio range. It may capture substantially enhancer-rich and testosterone-rich formulations, but it gives an accused party a potential noninfringement position if the ratio falls outside the range.

Claims 3 and 5: closed formulation language

Claims 3 and 5 use "consists of," unlike claim 1, which uses "comprising."

Claim 3 allows:

Testosterone;
Octyl salicylate or Padimate O;
Ethanol, isopropanol, or both; and
An optional gelling agent.

Claim 5 similarly identifies the formulation components and permits an optional gelling agent.

The practical effect is important. A formulation containing a preservative, surfactant, antioxidant, pH modifier, or other excipient may satisfy claim 1 but face a stronger challenge under claims 3 or 5 because of the closed-formulation language. The treatment of impurities, processing aids, residual water, and incidental ingredients would depend on the claim construction adopted in litigation.

Claims 6 and 7: method-of-use protection

The method claims require application of a composition that satisfies the composition limitations. They do not independently cover all methods of administering testosterone through the skin.

A product seller could face induced-infringement exposure if it markets a formulation with instructions that encourage application in a manner covered by claim 6 or claim 7. The scope would depend on the product’s actual formulation, label, promotional materials, and use instructions.

When does US Patent 8,784,878 lose exclusivity?

The patent’s ordinary expiration date is March 31, 2027, based on a March 31, 2006 priority date and the 20-year patent term applicable to the relevant US application.[1]

Milestone	Date
Earliest claimed priority	March 31, 2006
Patent issued	July 22, 2014
Ordinary 20-year expiration	March 31, 2027
Potential effective expiration	Ordinary expiration plus any recorded PTA

Patent expiration does not itself authorize a commercial launch before FDA approval. A generic applicant must still obtain approval under section 505(j) of the Federal Food, Drug, and Cosmetic Act or another applicable pathway.[2]

The patent does not receive biologic exclusivity because testosterone is a small-molecule active ingredient. Biosimilar provisions under section 351(k) of the Public Health Service Act are not relevant.[3]

What is the Orange Book status of US 8,784,878?

US 8,784,878 is part of the US patent estate associated with Lilly’s Axiron testosterone topical solution, NDA 022504. The Axiron patent estate has included formulation patents directed to testosterone, octyl salicylate, volatile alcohol solvents, and the amorphous-deposit delivery mechanism.[4]

Orange Book analysis should distinguish three categories:

Listed patents: Patents submitted by the NDA holder and accepted for listing against the reference drug.
Unlisted family members: Related patents that may be relevant commercially but are not listed against the NDA.
Expired or delisted patents: Patents whose Orange Book effect may have changed because of expiration, product discontinuation, or FDA listing updates.

For an ANDA applicant, a listed patent can generate a Paragraph IV certification and a potential 30-month stay if the NDA holder files timely infringement litigation.[2] The listing does not establish that every claim is valid or infringed.

Which companies have challenged the Axiron patent estate?

The main commercial challenge has come from generic manufacturers seeking approval for testosterone topical solution products equivalent or similar to Axiron. Publicly available ANDA and district-court records identify Paragraph IV litigation involving generic applicants and Lilly or related patent owners. The relevant disputes have focused on patent validity, claim construction, infringement, and the timing of generic entry rather than on biosimilar substitution.[5]

A complete diligence review should track:

The ANDA number;
The specific Orange Book patents cited in the Paragraph IV notice;
The filing date of the infringement complaint;
Any preliminary injunction or claim-construction ruling;
Settlement terms;
Authorized-generic provisions;
Launch dates; and
Whether the patent claims were invalidated, disclaimed, or survived.

The presence of litigation does not necessarily mean that US 8,784,878 was adjudicated invalid. Patent-by-patent and claim-by-claim review is required.

What generic entry risks exist for testosterone topical products?

A generic manufacturer faces four principal risk categories.

1. Ingredient-design risk

Avoiding octyl salicylate and Padimate O may reduce literal infringement risk under claim 1. The generic product would still need to demonstrate acceptable testosterone absorption and therapeutic equivalence.

2. Solid-state risk

The amorphous-deposit limitation may be the central technical battleground. A generic applicant may characterize its dried residue to establish that it does not contain the claimed amorphous phase. The patent owner may argue that the formulation inherently produces the claimed structure under normal use.

3. Concentration and ratio risk

A product can be designed outside the testosterone, enhancer, solvent, or molar-ratio ranges. Small formulation changes may affect bioavailability, evaporation behavior, skin tolerability, and FDA sameness requirements.

4. Method-of-use risk

Even if a generic manufacturer disputes composition claims, its labeling may create exposure under claims 6 and 7 if the label instructs users to apply the claimed formulation transdermally.

How does US 8,784,878 compare with other testosterone patent protections?

Protection type	What it protects	Relevance to 8,784,878
Active-ingredient patent	Testosterone molecule	Generally unavailable because testosterone is an established compound
Composition patent	Ingredients and concentration ranges	Core protection in US 8,784,878
Solid-state or deposition patent	Amorphous residue after evaporation	Distinguishing technical feature of this patent
Method-of-use patent	Applying the formulation to deliver testosterone	Claims 6 and 7
Manufacturing patent	Mixing, filling, or producing the dosage form	May create separate barriers
Orange Book-listed patent	Patent submitted against an approved NDA	May trigger Paragraph IV litigation
Regulatory exclusivity	FDA approval-based period	Separate from patent term

The patent is stronger against a close Axiron-style formulation than against a fundamentally different testosterone delivery system. A patch, metered-dose aerosol, tablet, implant, or formulation using a different penetration enhancer would present a different infringement analysis.

How strong is the patent estate for commercial purposes?

The estate is strongest where a competing product reproduces the following profile:

Testosterone in the claimed concentration range;
Octyl salicylate as the penetration enhancer;
Ethanol and/or isopropanol as the dominant volatile solvent;
Non-occlusive skin application;
Rapid solvent evaporation; and
An amorphous testosterone-containing residue.

The estate is weaker against products that use a different enhancer, a water-rich gel, a patch or occlusive system, a nonvolatile vehicle, or a delivery mechanism that does not produce the claimed amorphous deposit.

Validity risk would likely focus on written description, enablement, anticipation, obviousness, and whether the amorphous-deposit limitation is adequately supported and technically reproducible across the full claimed ranges. The broad concentration ranges and the functional solid-state limitation would be central to those arguments.

What licensing and commercial rights affect this patent?

The technology is associated with Acrux’s transdermal delivery platform and Lilly’s Axiron commercialization rights. Lilly marketed Axiron in the United States under NDA 022504, while Acrux supplied the underlying delivery technology and maintained patent interests in the platform.[4,6]

For licensing diligence, the relevant issues are:

Whether the patent was assigned or exclusively licensed;
Whether the license covered only Axiron or broader testosterone products;
Royalty obligations;
Sublicensing rights;
Territory restrictions;
Rights after product discontinuation;
Control of patent prosecution; and
Rights to enforce against generic applicants.

A commercial license does not expand the claim scope. It determines who can practice, enforce, or transfer the rights.

What manufacturing and geographic barriers remain?

US 8,784,878 is a US patent. It does not, by itself, block manufacture or sale in Europe, Canada, Japan, or other jurisdictions. Foreign protection must be assessed through the corresponding Patent Cooperation Treaty and national-phase family members.

Manufacturing risk is greater where the process is designed to preserve the claimed composition and produce the claimed amorphous deposit. Relevant process controls include:

Solvent ratios;
Mixing order;
Temperature;
Water content;
Gelling-agent addition;
Container closure;
Evaporation rate; and
Residual-solvent control.

A manufacturer may avoid a US claim while still infringing a corresponding foreign patent or a separate US family member. Family-level freedom-to-operate analysis is therefore necessary.

Key Takeaways

US 8,784,878 is a formulation and method patent for non-occlusive transdermal testosterone delivery.
Claim 1 requires testosterone, octyl salicylate or Padimate O, ethanol or isopropanol, defined weight ranges, and formation of an amorphous deposit after evaporation.
Claim 4 specifically targets octyl salicylate, the principal enhancer associated with Axiron-type products.
Claims 3 and 5 use closed-formulation language and are narrower than claim 1.
Claims 6 and 7 create method-of-use exposure based on application of the claimed formulations.
The ordinary patent expiration date is March 31, 2027, subject to recorded patent-term adjustment.
The patent is a small-molecule formulation patent, not a biologic patent, so biosimilar rules do not apply.
Generic risk is highest for products that replicate the Axiron ingredient system and amorphous-deposit behavior.
Alternative enhancers, solvent systems, delivery devices, and solid-state outcomes provide the principal design-around paths.
Orange Book listing, Paragraph IV certifications, litigation settlements, and family-member status must be reviewed separately from the claim text.

FAQs About US Patent 8,784,878

Does US 8,784,878 cover all testosterone gels?

No. It covers formulations with the specified testosterone, penetration enhancer, volatile solvent, concentration ranges, and amorphous-deposit limitation. Many testosterone gels fall outside one or more of those requirements.

Is octyl salicylate the same as octisalate?

Yes. Octyl salicylate is commonly called octisalate or ethylhexyl salicylate. The ingredient identity is relevant to claim 4 and to Axiron-type formulations.

Can a generic avoid the patent by replacing ethanol with another solvent?

Potentially. A formulation that does not contain ethanol, isopropanol, or a mixture of those solvents may avoid the literal solvent limitation. It must still satisfy FDA requirements for its proposed product.

Does patent expiration eliminate Paragraph IV risk immediately?

Expiration eliminates infringement liability for the expired patent, but regulatory timing, other listed patents, exclusivity, injunctions, and separate patent-family members may still affect launch timing.

Does the patent cover testosterone patches?

Not as a practical matter under the quoted claims. The claims require a volatile ethanol or isopropanol composition that forms an amorphous deposit after evaporation. A conventional occlusive patch uses a different dosage-form architecture.

References

United States Patent and Trademark Office. (2014). US Patent No. 8,784,878, Transdermal pharmaceutical composition comprising testosterone.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications.
U.S. Food and Drug Administration. (n.d.). Biosimilar and interchangeable biologic product standards.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book, NDA 022504.
United States District Court for the District of Delaware. (2014-2019). Lilly-related Axiron ANDA patent litigation records.
Eli Lilly and Company. (2010-2016). Annual reports and product information relating to Axiron testosterone topical solution.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003240301	⤷ Start Trial
Brazil	0312007	⤷ Start Trial
Brazil	PI0312007	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,784,878

Summary for Patent: 8,784,878